Public biotechs, ranked by BS score.
Pre-revenue biotechs are uniquely falsifiable: their entire valuation rests on whether one drug works. We extract the core hypothesis from SEC filings, score it against trial design quality, historical base-rates, and language red flags, then publish the result.
tracked
49
scored
46
HIGH
1
MEDIUM
20
LOW
25
| # | ticker | company | score | tier | phase | mkt cap | indication |
|---|---|---|---|---|---|---|---|
| 1 | CRBU | Caribou Biosciences, Inc. | 44.8 | LOW | PHASE1 | $189.4M | Lymphoma, Non-Hodgkin |
| 2 | UNCY | Unicycive Therapeutics, Inc. | 44.4 | LOW | PHASE2 | $167.8M | Chronic Kidney Disease Requiring Chronic Dialysis |
| 3 | EIKN | Eikon Therapeutics, Inc. | 43.6 | LOW | PHASE2 | $487.8M | Advanced Solid Tumor |
| 4 | SLDB | Solid Biosciences Inc. | 43.2 | LOW | PHASE3 | $797.0M | Catecholaminergic Polymorphic Ventricular Tachycardia |
| 5 | NVCT | Nuvectis Pharma, Inc. | 42.0 | LOW | PHASE1 | $216.2M | Advanced Solid Tumor |
| 6 | SEPN | Septerna, Inc. | 39.6 | LOW | PHASE1 | $1.12B | Healthy Volunteers |
| 7 | MLTX | MoonLake Immunotherapeutics | 38.4 | LOW | PHASE3 | $1.39B | Arthritis, Psoriatic |
| 8 | AGMB | Agomab Therapeutics NV | 38.0 | LOW | PHASE2 | $502.5M | Healthy Volunteers |
| 9 | MBX | MBX Biosciences, Inc. | 35.6 | LOW | PHASE1 | $1.56B | Postbariatric Hypoglycemia |
| 10 | VERA | Vera Therapeutics, Inc. | 35.2 | LOW | PHASE3 | $2.92B | IgA Nephropathy (IgAN) |
| 11 | DTIL | PRECISION BIOSCIENCES INC | 33.6 | LOW | PHASE2 | $170.6M | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD |
| 12 | SLNCF | Silence Therapeutics plc | 32.4 | LOW | PHASE2 | $283.4M | Cardiovascular Diseases |
| 13 | PLYX | Polaryx Therapeutics, Inc. | 29.6 | LOW | PHASE3 | $0 | Juvenile Neuronal Ceroid Lipofuscinosis |
| 14 | LXRX | LEXICON PHARMACEUTICALS, INC. | 28.4 | LOW | PHASE3 | $745.7M | Diabetic Nephropathies |
| 15 | DMAC | DiaMedica Therapeutics Inc. | 26.0 | LOW | PHASE3 | $333.0M | Stroke |
| 16 | SLN | Silence Therapeutics plc | 24.0 | LOW | PHASE2 | $274.0M | Cardiovascular Diseases |
| 17 | LRMR | Larimar Therapeutics, Inc. | 22.8 | LOW | PHASE2 | $528.8M | Friedreich Ataxia |
| 18 | DFTX | Definium Therapeutics, Inc. | 21.6 | LOW | PHASE3 | $2.14B | Generalized Anxiety Disorder |
| 19 | SVA | SINOVAC BIOTECH LTD | 19.6 | LOW | PHASE4 | $642.4M | Hand, Foot and Mouth Disease |
| 20 | EPRX | EUPRAXIA PHARMACEUTICALS INC. | 18.8 | LOW | PHASE2 | $435.4M | Eosinophilic Esophagitis |
| 21 | AMLX | Amylyx Pharmaceuticals, Inc. | 16.8 | LOW | PHASE3 | $1.91B | ALS |
| 22 | FBRX | Forte Biosciences, Inc. | 15.2 | LOW | PHASE2 | $470.7M | Alopecia Areata |
| 23 | NMRA | Neumora Therapeutics, Inc. | 14.8 | LOW | PHASE3 | $378.6M | Major Depressive Disorder |
| 24 | CRDL | Cardiol Therapeutics Inc. | 12.8 | LOW | PHASE3 | $154.1M | COVID-19 |
| 25 | ANTX | AN2 Therapeutics, Inc. | 4.4 | LOW | PHASE3 | $109.6M | Healthy Volunteers |